Compare ArcelorMittal SA (MT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs TG Therapeutics Inc — how do they compare? ArcelorMittal SA trades at $66.25 (market cap $50.01B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: ArcelorMittal SA is far larger — about 6.1× TG Therapeutics Inc's market cap, and ArcelorMittal SA pays a 0.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MT | TGTX | |
|---|---|---|
Market Cap | $50.01B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $71.65 | $59.06 |
52-Week Low | $30.39 | $26.39 |
Enterprise Value | $59.33B | $8.50B |
Dividend Yield | 0.91% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
